Zhejiang Kanglaite Group will start a large US Phase III trial of its lead drug, Kanglaite, a TCM-derived medication, in patients with pancreatic cancer. The company says Kanglaite Injection is a novel dual-function drug that kills cancer cells while strengthening immune function. Its active ingredient is derived from coix, a grass related to rice and maize. The trial of the drug, which has been approved in China since 1995, will be conducted by Kanglaite’s US subsidiary.
Help employers find you! Check out all the jobs and post your resume.
